The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant 177 Lu-PNT2002 before SBRT significantly improved progression-free survival in PSMA PET/CT–detected oligorecurrent hormone-sensitive prostate cancer, with median 17.6 vs 7.4 months.
- Why it matters: Oligorecurrent orHSPC treated with SBRT alone often progresses on PSMA PET/CT, and better strategies are needed to extend control and delay subsequent hormonal therapy.
- What they did: In the randomized phase 2 LUNAR trial, 92 patients (1–5 SBRT-amenable lesions) received SBRT alone or two cycles of neoadjuvant 177 Lu-PNT2002 plus SBRT, with PFS defined by PSMA PET/CT new lesions, salvage hormonal therapy initiation, or death.
- The result: At median 31.9 months follow-up, 177 Lu-PNT2002 improved PFS (HR 0.38, 95% CI 0.23–0.61; p<0.001) and hormonal therapy–free survival (HR 0.57, 95% CI 0.34–0.95; p=0.03), with no new safety signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.